Angiographic Delivery of AD-MSC for Ulcerative Colitis

Inclusion Criteria: * Males and Females 18-65 years of age. * Moderate to Severe medically refractory inflammatory ulcerative colitis: * as defined by a an Adapted Mayo Score of 5to 9 points * including an endoscopic sub-score of 2 or 3 * Concurrent therapies with corticosteroids, 5-ASA drugs, thiopurines, MTX, antibiotics, anti-TNF, and anti-integrin therapy are permitted. * To meet the definition of refractory UC, all patients must have failed at least 2 standard FDA approved medications for the treatment of UC * Current standard therapy includes 5-ASA products, thiopurines, anti-TNF therapy, ustekinemab, vedolizumab, and tofacitinib (i.e. all FDA approved therapies for UC). * Refractory and failure to response is defined as continued symptoms despite 12 weeks of therapy at FDA approved doses by product necessitating change in medical strategy or referral for colectomy. * All patients should have undergone a colonoscopy in last 12 months to rule out malignant or premalignant condition * Female subjects that are of child bearing potential must to agree to use effective contraception method(s) for the duration of the study * Hemoglobin must be greater than 8 * INR must be less than 1.5 * Ability to comply with protocol * Competent and able to provide written informed consent Exclusion Criteria: * Inability to give informed consent. * Clinically significant medical conditions within the six months before administration of MSCs: e.g. myocardial infarction, active a…